Skip to main content

Table 2 Study outcomes

From: Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]

Parameter

Control

Group A

Group B

Total units transfused

138

33*

23*

% of transfused patients

58.3

37.3*

26.5*

Units transfused per patient

2.83 ± 3.9

0.64 ± 1.0*

0.47 ± 0.9*

Units transfused per transfused patient

4.86 ± 4.0

1.74 ± 0.7*

1.77 ± 0.7*

Volume of RBCs transfused per day

43.2 ± 61.1

11.3 ± 20.3*

16.1 ± 36.1*

Average days transfused

1.60 ± 2.2

0.59 ± 0.9*

0.35 ± 0.7*

Hct (%) at day 28

30.4 ± 4.5

33.3 ± 5.3*

37.5 ± 5.8* †

Hb (mg/dl) at day 28

9.9 ± 1.5

10.7 ± 1.9

11.6 ± 1.9*

ΔHct (%)

2.09 ± 5.0

5.53 ± 5.5*

8.76 ± 6.2* †

ΔHb (mg/dl)

0.69 ± 1.5

1.43 ± 1.7

2.24 ± 6.2*

  1. *P < 0.05 versus control; †P < 0.05 versus group A. ΔHb, mean increase in Hb from baseline to final measurement; ΔHct, mean increase in Hct from baseline to final measurement; Hb, haemoglobin; Hct, haematocrit; RBC, red blood cell.
Back to article page

Critical Care

ISSN: 1364-8535